Alessandro De Vita Selected Research

Alessandro De Vita Research Topics

Disease

26	Neoplasms (Cancer) 06/2022 - 01/2014
10	Sarcoma (Soft Tissue Sarcoma) 03/2022 - 12/2015
8	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2014
6	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2014
3	Triple Negative Breast Neoplasms 01/2022 - 11/2016
2	Hypoxia (Hypoxemia) 01/2022 - 01/2019
2	Neutropenia 11/2019 - 01/2017
2	Neuroendocrine Carcinoma 01/2018 - 01/2015
2	Prostatic Neoplasms (Prostate Cancer) 11/2017 - 10/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 05/2022
1	Inflammation (Inflammations) 03/2022
1	Desmoplastic Fibroma 02/2022
1	Giant Cell Tumor of Bone 02/2022
1	Hamartoma 05/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Back Pain (Backache) 11/2019
1	Bone Fractures (Bone Fracture) 11/2019
1	Pain (Aches) 11/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2019
1	Febrile Neutropenia 01/2017
1	Liposarcoma 12/2016
1	Leiomyosarcoma 12/2015
1	Pleural Effusion (Pleural Effusions) 12/2014
1	Edema (Dropsy) 12/2014
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2014
1	Dyspnea (Shortness of Breath) 12/2014
1	Bone Diseases (Bone Disease) 09/2014

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2017
4	CollagenIBA 01/2022 - 06/2017
4	Zoledronic Acid (Zometa)FDA Link 06/2019 - 09/2014
3	Everolimus FDA Link 06/2022 - 11/2016
3	Biological ProductsIBA 01/2022 - 11/2017
3	TrabectedinIBA 05/2021 - 12/2015
3	Epirubicin (Ellence)FDA LinkGeneric 01/2021 - 01/2017
3	Ifosfamide FDA LinkGeneric 12/2017 - 12/2015
3	AnthracyclinesIBA 01/2017 - 12/2015
3	Denosumab FDA Link 11/2016 - 09/2014
2	Tyrosine Kinase InhibitorsIBA 02/2022 - 01/2020
2	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2020
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2021 - 01/2021
2	Phosphotransferases (Kinase)IBA 05/2021 - 01/2021
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 11/2017
2	Capecitabine (Xeloda)FDA Link 01/2021 - 01/2014
2	Filgrastim (Neupogen)FDA Link 11/2019 - 01/2017
2	eribulin FDA Link 12/2017 - 12/2016
1	Sirolimus (Rapamycin)FDA Link 06/2022
1	terephthalic acid (terephthalate)IBA 03/2022
1	butyleneIBA 03/2022
1	HydrogelsIBA 03/2022
1	Interleukin-10 (Interleukin 10)IBA 03/2022
1	CytokinesIBA 03/2022
1	Ethylene Oxide (Oxirane)IBA 03/2022
1	GelatinIBA 03/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	ResveratrolIBA 01/2022
1	Lysosomal-Associated Membrane Protein 1IBA 01/2022
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 05/2021
1	LipidsIBA 01/2021
1	tyrosine receptor (receptor, tyrosine)IBA 01/2021
1	Trefoil Factor-1IBA 01/2021
1	larotrectinibIBA 01/2021
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2021
1	Estrogen ReceptorsIBA 01/2021
1	MTOR InhibitorsIBA 01/2020
1	pazopanib FDA Link 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Tamoxifen FDA LinkGeneric 11/2019
1	Vitamin D FDA LinkGeneric 11/2019
1	TOR Serine-Threonine KinasesIBA 06/2019
1	Antineoplastic Agents (Antineoplastics)IBA 12/2017
1	Edotreotide (SMT 487)IBA 11/2017
1	GalliumIBA 11/2017
1	FluorineIBA 11/2017
1	Prostate-Specific Antigen (Semenogelase)IBA 11/2017
1	Choline (Choline Chloride)IBA 11/2017
1	Collagen Type I (Type I Collagen)IBA 06/2017
1	Pharmaceutical PreparationsIBA 02/2017
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2017
1	LenograstimIBA 01/2017
1	Biosimilar PharmaceuticalsIBA 01/2017
1	Conditioned Culture MediaIBA 01/2017
1	taxaneIBA 12/2016
1	RANK LigandIBA 10/2016
1	Monoclonal AntibodiesIBA 10/2016
1	OsteoprotegerinIBA 10/2016
1	DNA (Deoxyribonucleic Acid)IBA 12/2015
1	Alkylating AgentsIBA 12/2015
1	PlatinumIBA 01/2015
1	Imatinib Mesylate (Gleevec)FDA Link 12/2014
1	ElectrolytesIBA 12/2014
1	Macrophage Colony-Stimulating FactorIBA 09/2014

Therapy/Procedure

8	Therapeutics 03/2022 - 01/2017
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2015
1	Precision Medicine 05/2022
1	Immunotherapy 07/2021
1	Adjuvant Chemotherapy 11/2017
1	Radiotherapy 11/2017